Profile Picture
Google ScholarScopusORCIDPublons
Kurumdan Ayrılmıştır
Organizational Units
Job Title
First Name
Last Name
Email Address
Birth Date

Search Results

Now showing 1 - 1 of 1
  • PublicationOpen Access
    Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.
    (2016-01-01) LÜ, J; ZHANG, J; JIANG, C; DENG, Y; Özten, NUR; BOSLAND, MC; ÖZTEN KANDAŞ, NUR
    The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of non-small cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify two major lessons from the outcomes of these trials: 1) The antioxidant hypothesis was tested in wrong subjects or patient populations. 2) The selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to re-vitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.